We demonstrate that GIPR and GLP1R agonism additively attenuate hepatic steatosis, lower inflammation, ameliorate liver injury, and together prevent the development of NAFLD. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.